226 related articles for article (PubMed ID: 31554271)
41. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
42. The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.
Reinholdt L; Laursen MB; Schmitz A; Bødker JS; Jakobsen LH; Bøgsted M; Johnsen HE; Dybkær K
Biomark Res; 2016; 4():12. PubMed ID: 27307990
[TBL] [Abstract][Full Text] [Related]
43. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
[TBL] [Abstract][Full Text] [Related]
44. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
45. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
Li T; Li H; Wang Y; Harvard C; Tan JL; Au A; Xu Z; Jablons DM; You L
J Pathol; 2011 Mar; 223(4):519-30. PubMed ID: 21294125
[TBL] [Abstract][Full Text] [Related]
46. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
[TBL] [Abstract][Full Text] [Related]
47. Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.
Cambruzzi E
World Neurosurg; 2020 Feb; 134():215-220. PubMed ID: 31605845
[TBL] [Abstract][Full Text] [Related]
48. Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion.
Miyanishi N; Suzuki Y; Simizu S; Kuwabara Y; Banno K; Umezawa K
Biochem Biophys Res Commun; 2010 Dec; 403(1):154-9. PubMed ID: 21059341
[TBL] [Abstract][Full Text] [Related]
49. LncRNA COL1A1-014 is involved in the progression of gastric cancer via regulating CXCL12-CXCR4 axis.
Dong XZ; Zhao ZR; Hu Y; Lu YP; Liu P; Zhang L
Gastric Cancer; 2020 Mar; 23(2):260-272. PubMed ID: 31650323
[TBL] [Abstract][Full Text] [Related]
50. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
51. [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].
Wu L; Zhang YZ; Xia B; Li XW; Yuan T; Tian C; Zhao HF; Yu Y; Sotomayor E
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1036-1042. PubMed ID: 29365396
[No Abstract] [Full Text] [Related]
52. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
Guo Q; Wu XH; Lü YP; Yang B; Xu F; Zhang SJ
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(21):1677-80. PubMed ID: 24125682
[TBL] [Abstract][Full Text] [Related]
53. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells.
Shen B; Zheng MQ; Lu JW; Jiang Q; Wang TH; Huang XE
Asian Pac J Cancer Prev; 2013; 14(9):5403-8. PubMed ID: 24175834
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
55. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract][Full Text] [Related]
56. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
57. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
[TBL] [Abstract][Full Text] [Related]
58. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system.
Chiaramonte R; Colombo M; Bulfamante G; Falleni M; Tosi D; Garavelli S; De Simone D; Vigolo E; Todoerti K; Neri A; Platonova N
Int J Biochem Cell Biol; 2015 Sep; 66():134-40. PubMed ID: 26235278
[TBL] [Abstract][Full Text] [Related]
59. CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer.
Yu X; Shi W; Zhang Y; Wang X; Sun S; Song Z; Liu M; Zeng Q; Cui S; Qu X
Sci Rep; 2017 Feb; 7():42226. PubMed ID: 28176874
[TBL] [Abstract][Full Text] [Related]
60. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/CXCR4 pathway.
Gao XL; Zheng M; Wang HF; Dai LL; Yu XH; Yang X; Pang X; Li L; Zhang M; Wang SS; Wu JB; Tang YJ; Liang XH; Tang YL
BMC Cancer; 2019 Jul; 19(1):743. PubMed ID: 31357956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]